Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ipsen Pharma

< Previous 1 2 Next >
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
From Ipsen Pharma
Via GlobeNewswire
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen announces issuance of €500 million inaugural Rated Public Bond
From Ipsen Pharma
Via GlobeNewswire
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
From Ipsen Pharma
Via GlobeNewswire
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
From Ipsen Pharma
Via GlobeNewswire
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
From Ipsen Pharma
Via GlobeNewswire
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen receives its second Shingo Prize for operational excellence
From Ipsen Pharma
Via GlobeNewswire
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
From Ipsen Pharma
Via GlobeNewswire
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
From Ipsen Pharma
Via GlobeNewswire
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
From Ipsen Pharma
Via GlobeNewswire
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
From Ipsen Pharma
Via GlobeNewswire
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
From Ipsen Pharma
Via GlobeNewswire
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
From Ipsen Pharma
Via GlobeNewswire
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
From Ipsen Pharma
Via GlobeNewswire
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
From Ipsen Pharma
Via GlobeNewswire
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
From Ipsen Pharma
Via GlobeNewswire
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
From Ipsen Pharma
Via GlobeNewswire
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
From Ipsen Pharma
Via GlobeNewswire
Ipsen appoints Keira Driansky as EVP, President of North America
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
From Ipsen Pharma
Via GlobeNewswire
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
From Ipsen Pharma
Via GlobeNewswire
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
From Ipsen Pharma
Via GlobeNewswire
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
From Ipsen Pharma
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS